2 Top Pot Stocks Under $5 to Buy Today

CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST) and Khiron Life Sciences Corp. (TSXV:KHRN) are attractively valued and poised to soar.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

There are rising fears that the hype surrounding cannabis stocks has abruptly ended and the bubble is about to burst. While a reckoning is looming for an industry in which many companies sport nosebleed valuations, it is undeniable that legal marijuana is here to stay.

The latest cannabis stock sell-off has created several bargain basement investments with the potential to soar and deliver outsized returns. Here are two marijuana stocks trading at less than $5 at writing that should be on every cannabis investors radar.

Punished after recent regulatory breaches

CannTrust Holdings (TSX:TRST)(NYSE:CTST) has been heavily penalized by the market after announcing that the Canadian cannabis regulator Health Canada had identified a series of compliance breaches, which sees it down by 41% since the start of 2019 and trading at around $3.90 per share at writing. This creates an opportunity to acquire a quality cultivator at a deep discount to its peers.

CannTrust’s issues relate to the cultivation of cannabis in unlicensed facilities between October 2018 and March 2019. As a result of Health Canada’s findings, it has placed a voluntary hold on the sale and shipment of all cannabis products, while Health Canada evaluates its growing and processing facilities.

Clearly, this will have a significant short-term impact on the cultivators 2019 performance and earnings, although it’s unclear just how significant that will be. Health Canada will also likely order the completion of remedial actions and other sanctions, including what could amount to costly fines.

Nonetheless, CannTrust possesses quality assets and is continuing to grow as well as process cannabis at its licensed facilities. In a push to reduce costs and boost margins, it has acquired 81 acres in British Columbia to be used for outdoor cultivation. Canadian growers are increasingly recognizing the need to reduce the environmental footprint and high costs associated with climate-controlled greenhouse cultivation.

CannTrust, in comparison with many of its Canadian peers, is already a low cost grower, reporting first-quarter 2019 cost of sales of $3.03 per gram, which is lower than Canopy and Aphria. The move to outdoor cultivation will see costs fall further, boosting profitability.

While the fallout from the recent investigation by Health Canada is impossible to predict, it’s likely to be far less severe than the market believes, making now the time to buy CannTrust.

Low-cost Colombian cultivator

Latin American-focused cannabis company Khiron Life Sciences (TSXV:KHRN), despite being roughly handled by the market in recent weeks, is up by 25% year to date to be trading at $1.90 at writing. Its cultivating operations are focused on Colombia, where it has 1.9 million square feet of licenses cultivating area with 100,000 kilograms of production capacity. Khiron claims to be producing dried flower with an average cost of goods sold of $0.35 per gram.

Its Colombian operations are expected to commence commercial production during the third quarter 2019, with all cultivation, extraction and testing facilities operational. Khiron will have capacity to produce 25,000 kilograms of dried flower annually and could be producing up to 158,000 kilograms annually once construction of all licensed cultivation areas is competed.

Testing of the Colombian crop currently being grown shows an absence of mould, fungus and pesticides or other harmful compounds.

Khiron is also building a large regional distribution platform, including access to 176 retail outlets in Colombia for its CBD wellness products. Its medical marijuana products have been endorsed by six Latin American medical associations that represent 5,000 doctors with approximately 1 million patients among them. Khiron anticipates commercially launching its medical cannabis products during the second half of 2019.

These events, if successfully executed, which is highly likely, will give Khiron’s stock a solid boost and position it to report stronger earnings for the remainder of 2019 and into 2020.

Foolish takeaway

CannTrust and Khiron offer the opportunity to gain low cost exposure to the burgeoning global cannabis industry, which has been estimated by investment bank Jeffries Group to be worth US$130 billion by 2029. This assumes that major Latin American and European jurisdictions as well as the U.S. will legalize recreational and medical marijuana over the coming decade.

That along with CannTrust and Khiron’s attractive valuations makes now the time to acquire both cannabis cultivators before they soar in value.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Matt Smith has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »